EP
Eversept Partners Portfolio holdings
AUM
$992M
This Quarter Return
+7.55%
1 Year Return
+2.54%
3 Year Return
+103.47%
5 Year Return
+181.01%
10 Year Return
–
AUM
$350M
AUM Growth
+$350M
(+3.6%)
Cap. Flow
-$4.54M
Cap. Flow
% of AUM
-1.3%
Top 10 Holdings %
Top 10 Hldgs %
61.71%
Holding
69
New
18
Increased
19
Reduced
16
Closed
8
Top Buys
| 1 |
The Ensign Group
ENSG
|
$8.31M |
| 2 |
Illumina
ILMN
|
$6.73M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$6.32M |
| 4 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
$6.04M |
| 5 |
Centene
CNC
|
$3.99M |
Top Sells
| 1 |
NUVA
NuVasive, Inc.
NUVA
|
$14M |
| 2 |
Sarepta Therapeutics
SRPT
|
$10.2M |
| 3 |
AMRN
Amarin Corp
AMRN
|
$9.74M |
| 4 |
ABMD
Abiomed Inc
ABMD
|
$7.81M |
| 5 |
AERI
Aerie Pharmaceuticals, Inc.
AERI
|
$5.45M |
Sector Composition
| 1 | Healthcare | 76.2% |
| 2 | Industrials | 9.7% |
| 3 | Financials | 4.4% |
| 4 | Real Estate | 1.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RCM
1
DELISTED
R1 RCM Inc. Common Stock
RCM
| $34M | 9.51% | 2,699,159 -264,500 | -9% | -$3.33M |
|
|
AMRN
2
Amarin Corp
AMRN
$311M
| $30.2M | 8.46% | 1,558,065 -502,222 | -24% | -$9.74M |
|
3
GSK
GSK
$79.9B
| $28.1M | 7.87% | 693,685 -109,500 | -14% | -$4.43M |
|
|
ZGNX
4
DELISTED
Zogenix, Inc.
ZGNX
| $25.6M | 7.18% | 536,794 +41,365 | +8% | +$1.98M |
|
5
Danaher
DHR
$147B
| $20.8M | 5.81% | 145,104 -13,660 | -9% | -$1.95M |
|
|
6
The Ensign Group
ENSG
$9.91B
| $17.4M | 4.87% | 305,483 +145,938 | +91% | +$8.31M |
|
|
RDUS
7
DELISTED
Radius Health, Inc.
RDUS
| $17.3M | 4.85% | 710,517 +65,100 | +10% | +$1.59M |
|
8
Ascendis Pharma
ASND
$11.8B
| $15.7M | 4.4% | 136,397 +33,101 | +32% | +$3.81M |
|
9
eHealth
EHTH
$118M
| $15.4M | 4.31% | 178,739 -21,910 | -11% | -$1.89M |
|
10
Sanofi
SNY
$121B
| $11.5M | 3.22% | 266,062 -66,340 | -20% | -$2.87M |
|
11
Vertex Pharmaceuticals
VRTX
$100B
| $10.6M | 2.97% | 57,849 +19,620 | +51% | +$3.6M |
|
12
TG Therapeutics
TGTX
$4.65B
| $7.64M | 2.14% | 883,501 +134,907 | +18% | +$1.17M |
|
|
DCPH
13
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $6.88M | 1.93% | 305,233 +54,801 | +22% | +$1.24M |
|
14
argenx
ARGX
$43.6B
| $6.83M | 1.91% | 48,264 +8,930 | +23% | +$1.26M |
|
|
15
Illumina
ILMN
$15.8B
| $6.73M | 1.89% | +18,290 | New | +$6.73M |
|
|
16
Alnylam Pharmaceuticals
ALNY
$58.5B
| $6.32M | 1.77% | +87,140 | New | +$6.32M |
|
|
BOLD
17
DELISTED
Audentes Therapeutics, Inc
BOLD
| $6.04M | 1.69% | +159,526 | New | +$6.04M |
|
|
NUVA
18
DELISTED
NuVasive, Inc.
NUVA
| $5.37M | 1.5% | 91,798 -238,803 | -72% | -$14M |
|
|
19
Centene
CNC
$14.3B
| $5.22M | 1.46% | 99,600 +76,000 | +322% | +$3.99M |
|
|
ARQL
20
DELISTED
Arqule Inc
ARQL
| $4.97M | 1.39% | 451,688 -195,230 | -30% | -$2.15M |
|
21
Fate Therapeutics
FATE
$120M
| $4.42M | 1.24% | 217,856 -132,155 | -38% | -$2.68M |
|
|
ARNA
22
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $4.31M | 1.21% | 73,501 -2,220 | -3% | -$130K |
|
|
DERM
23
DELISTED
Dermira, Inc.
DERM
| $3.82M | 1.07% | 399,874 +220,374 | +123% | +$2.11M |
|
|
TCDA
24
DELISTED
Tricida, Inc. Common Stock
TCDA
| $3.46M | 0.97% | 87,568 +38,060 | +77% | +$1.5M |
|
25
MacroGenics
MGNX
$112M
| $3.23M | 0.91% | +190,623 | New | +$3.23M |
|